Against prostate cancer!

ArticleMedicine Guanlan

On December 6, Impair Pharmaceuticals announced that its PARP inhibitor senaparib (IMP4297) for the treatment of prostate cancer has been approved by the China National Medical Products Administration (NMPA) for a clinical trial application

Impair Pharmaceutical focuses on the "synthetic lethal" mechanism of action, and the company's president and chief executive officer is Dr.

Senaparib, independently developed by Impair Pharmaceuticals, is also an oral small molecule PARP inhibitor

According to the information on the official website of Impair Pharmaceuticals, senaparib is currently undergoing a number of clinical studies worldwide, including phase 3 clinical studies for the first-line maintenance treatment of ovarian cancer, phase 2 clinical studies for ovarian cancer third-line and above BRCA mutant populations, and senaparib Combined with temozolomide (TMZ) for phase 1/2 clinical studies of advanced solid tumors and small cell lung cancer

According to the press release, the approval of senaparib is a randomized, double-blind, multi-center, placebo-controlled, global multi-center clinical study aimed at obtaining partial or complete response to docetaxel treatment or homologous recombination with stable disease In subjects with metastatic castration-resistant prostate cancer (mCRPC) with repair (HRR) gene mutations, the effectiveness and safety of senaparib as a maintenance treatment for these patients were evaluated

Public information shows that prostate cancer is the second most common cancer among men

It is worth mentioning that Impair Pharmaceuticals has reached a strategic cooperation agreement with Junshi Biologics in August 2020.

Reference materials:

[1] Impair Pharma’s PARP inhibitor Senaparib was approved for prostate cancer in China, Retriewved Dec 6, 2021, from https://mp.

[2] Impact Pharma’s PARP inhibitor Senaparib was approved for clinical use in the United States for targeting prostate cancer.